Acalabrutinib for mantle cell lymphoma

Thomas E. Witzig, David Inwards

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

Original languageEnglish (US)
Pages (from-to)2570-2574
Number of pages5
JournalBlood
Volume133
Issue number24
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Acalabrutinib for mantle cell lymphoma'. Together they form a unique fingerprint.

  • Cite this